SLC5A2 and type 2 diabetes mellitus: The results of these different clinical trials all pointed to the fact that the combinations of metformin and different SGLT2 inhibitor drugs have an encouraging efficacy in the management of T2D, including better glycemic improvements, weight loss, blood pressure control, etc. In addition to these advantages, the combination of metformin-SGLT2 inhibitors also showed potential benefits in cardiovascular and renal protection, providing comprehensive protection for patients with T2D (135, 137).